James F. Widergren
Mr. Widergren joined Corgenix as President in March 2015 with the purchase of Corgenix by Orgentec Diagnostica. Jim Widergren is a former Senior Vice President of Global Customer Operations at Beckman Coulter. He was responsible for all sales, service and customer support operations worldwide. Prior to this position, Mr. Widergren was the Group Vice President for the Chemistry and Automation Systems Business Group, Corporate Vice President for Asia Pacific and Latin America Commercial Operations and Vice President and Treasurer of Beckman Coulter.
Prior to joining Beckman Coulter in 1992, he held financial management positions with Ferguson Partners, a commercial real estate development firm and Malcolm Lewis Associates, a consulting firm, and was an applications engineer with Allied Signal Corp. In addition, he conducted research on economic development in Asia as a Fellow of the Thomas J. Watson Foundation.
A Registered Professional Mechanical Engineer (PE) in California, Widergren holds a Bachelor of Science degree in Engineering and a Master of Engineering degree from Harvey Mudd College, Claremont, CA, a Master of Business Administration degree from the University of California at Los Angeles, and completed the Stanford Executive Program at Stanford University, Palo Alto, CA.
Kelly R. Pitts, Ph.D.
Vice President, Research and Development; Site Manager – Colorado Operations
Dr. Pitts joined Corgenix in 2011. Prior to arriving at Corgenix, Dr. Pitts was the Global Group Leader for the Global Bioassay Group tasked with developing and maintaining both commercial and development potency methods at Amgen, Inc. While at Gilead Sciences, Inc. and Myogen, Inc., Dr. Pitts led the Molecular Pharmacology department, where his group developed cell- and tissue-based methods for determining drug candidate mechanism of action in cardiovascular, pulmonary, renal, and hepatic therapeutic areas. Dr. Pitts has extensive experience in developing biomarker-driven assays to support discovery research, clinical development, and commercialization of small-molecule and biologic-based drugs. He continues to maintain a broad interest in clinical biomarkers, detection technologies, and drug pharmacology, and has published several peer-reviewed manuscripts in these fields.
Pitts holds a Bachelors of Science degree from Brigham Young University and a Doctorate degree from Mayo Graduate School, Mayo Clinic (Rochester). Dr. Pitts is a current associate editor for the Journal of Pharmacological and Toxicological Methods, and is a former appointed Chair of the Physiologists in Industry Committee of the American Physiological Society. He is also a registered Patent Agent with the United States Patent and Trademark Office.
Taryn G. Reynolds
Vice President Information Technology and Facilities
Mr. Reynolds joined the Company in 1992. Prior to joining Corgenix, Mr. Reynolds held executive positions at Brinker International, MJAR Corporation and M&S Incorporated, international and Colorado based property, operational and financial management firms.
Vice President, Business Development, Personalized Diagnostics
MMs. McHugh joined the Company in 2017. Prior to joining Corgenix, Dawn was a Director of Pharma Partnering at QIAGEN, where she spent 5.5 years as a member of the Companion Diagnostics Business Development Team, responsible for establishing collaborations with Pharma, for the development, registration and commercialization of Molecular Companion Diagnostics. Prior to joining QIAGEN, Dawn worked at LLNS in NYC and managed the advertising team that developed a global campaign for the launch of a first-in-class therapy for the treatment of ALK-positive non-small cell lung carcinoma (NSCLC). Dawn’s other experience spans the oncology therapeutic and diagnostic markets with roles at AstraZeneca (Oncology Sales), Becton Dickinson (Oncology Diagnostic Marketing), and Oncor, Inc. (Diagnostic Sales, Product Management and Marketing). Ms. McHugh holds a Bachelor’s of Science degree in Biology from Stony Brook University in Stony Brook, New York and a Master’s of Science degree in Human Cytogenetics from Hofstra University in Hempstead, NY.